Avon’s Pink Ribbon Cosmetics Case Carries Make-up And a Message

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

NEW YORK--Avon’s Breast Cancer Awareness Crusade is combining health and beauty with the introduction of its newest fundraising product, the Avon Pink Ribbon Cosmetics Case.

 NEW YORK--Avon’s Breast Cancer Awareness Crusade is combining health and beauty with the introduction of its newest fundraising product, the Avon Pink Ribbon Cosmetics Case.

The cosmetics case joins Avon’s other pink ribbon products, including a pin and coffee mug, proceeds of which have helped Avon’s Crusade raise more than $25 million for US nonprofit breast health programs nationwide and contributed to the Avon Worldwide Fund for Women’s Health, a global initiative that is expected to reach the $50 million fundraising mark in 1998.

"The message we are bringing to women this year is: Claim Your Health, Claim Your Beauty," said Joanne Mazurki, director of Avon’s Crusade. "We are reminding women that along with their daily beauty routines, they should be equally diligent about practicing good breast health."

The Cosmetics Case will be available in October at a price of $3.00. To order, contact the nearest Avon Sales Representative or call 1-800-FOR-AVON.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content